Mary E Taplin

Summary

Affiliation: University of Massachusetts Medical School
Country: USA

Publications

  1. ncbi request reprint Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:5408-13. 2006
  2. doi request reprint Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
  3. ncbi request reprint Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
  4. doi request reprint Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
  5. ncbi request reprint A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
  6. ncbi request reprint Drug insight: role of the androgen receptor in the development and progression of prostate cancer
    Mary Ellen Taplin
    Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Nat Clin Pract Oncol 4:236-44. 2007
  7. ncbi request reprint Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:8109-13. 2005
  8. ncbi request reprint The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes
    Mary Ellen Taplin
    J Clin Oncol 21:3552-3. 2003
  9. ncbi request reprint Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 96:783-6. 2005
  10. ncbi request reprint Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer
    Mark Pomerantz
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    J Urol 177:2146-50. 2007

Detail Information

Publications14

  1. ncbi request reprint Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:5408-13. 2006
    ..The purpose of this trial was to determine the feasibility, toxicity, and prostate-specific antigen (PSA) response of chemotherapy and limited ADT for men with PSA relapse...
  2. doi request reprint Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
    ..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases...
  3. ncbi request reprint Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
    ..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation. Materials and..
  4. doi request reprint Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  5. ncbi request reprint A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
    ..The authors conducted a phase 2 trial of docetaxel plus carboplatin chemotherapy in this disease setting...
  6. ncbi request reprint Drug insight: role of the androgen receptor in the development and progression of prostate cancer
    Mary Ellen Taplin
    Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Nat Clin Pract Oncol 4:236-44. 2007
    ..The biology of androgen independence and the development of new approaches targeting AR signaling are reviewed herein...
  7. ncbi request reprint Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:8109-13. 2005
    ..We assessed factors predicting a successful tumor harvest from bone marrow biopsies (BMBx) in castration-resistant metastatic prostate cancer patients...
  8. ncbi request reprint The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes
    Mary Ellen Taplin
    J Clin Oncol 21:3552-3. 2003
  9. ncbi request reprint Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 96:783-6. 2005
    ....
  10. ncbi request reprint Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer
    Mark Pomerantz
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    J Urol 177:2146-50. 2007
    ..We tested 2 doses of the conjugated estrogen Premarin(R) in patients with androgen independent prostate cancer to determine the efficacy and safety of this widely available medication...
  11. ncbi request reprint Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study
    Mary Ellen Taplin
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 66:386-91. 2005
    ..Plasma CgA levels in patients with prostate cancer may reflect the extent of the tumor neuroendocrine phenotype...
  12. doi request reprint Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
    ..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)...
  13. ncbi request reprint Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115 6084, USA
    J Cell Biochem 91:483-90. 2004
    ..Understanding the changes in AR signaling in the evolution of androgen-independent prostate cancer will be key to the development of more effective hormone therapy...
  14. doi request reprint A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1084-9. 2008
    ..To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites..